BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2021

May 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2021-04-30

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-30	Common Stock	A	341	$62.407	Acquired	303839	Direct
2021-05-06	Common Stock	M	25000	$26.49	Acquired	328839	Direct
2021-05-06	Common Stock	S	14825	$78.012	Disposed	314014	Direct
2021-05-06	Common Stock	S	10175	$78.690	Disposed	303839	Direct
2021-05-07	Common Stock	M	25000	$26.49	Acquired	328839	Direct
2021-05-07	Common Stock	S	15556	$77.60	Disposed	313283	Direct
2021-05-07	Common Stock	S	6115	$78.769	Disposed	307168	Direct
2021-05-07	Common Stock	S	3329	$79.394	Disposed	303839	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-06	Stock Option (Right to buy Common Stock)	$26.49	M	25000	Disposed	2021-05-11	Common Stock (25000)	Direct
2021-05-07	Stock Option (Right to buy Common Stock)	$26.49	M	25000	Disposed	2021-05-11	Common Stock (25000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	247533	Indirect

Footnotes

F1: Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan.

F2: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021.

F3: The price in column 4 is the weighted average price. The price actually received ranged from $77.375 to $78.37. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F4: The price in column 4 is the weighted average price. The price actually received ranged from $78.38 to $78.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F5: The price in column 4 is the weighted average price. The price actually received ranged from $77.13 to $77.95. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F6: The price in column 4 is the weighted average price. The price actually received ranged from $78.15 to $79.14. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F7: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $77.9400 on March 4, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.

F8: The price in column 4 is the weighted average price. The price actually received ranged from $79.15 to $79.75. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F9: Reflects the number of options outstanding after the transactions from this specific stock option grant.